How to buy Axon Enterprise (AXON) stock from India

Yes, an Indian resident can buy Axon Enterprise — legally, in US dollars, under the RBI's Liberalised Remittance Scheme (LRS). The buying is the easy 10%. The 90% that decides your outcome is tax, estate-tax exposure, and position sizing. AXON has one helpful quirk: no dividend, so US withholding and Form 67 paperwork are a non-issue. This is the short version.

The 30-second version

• Legal and simple. Buy AXON via any India-facing platform (Vested, INDmoney) or a global broker (Interactive Brokers, Rovia). Whole shares or a fractional rupee amount — fractional matters here because AXON trades in the hundreds of dollars.
• Pure capital-gains play. AXON has never paid a dividend and reinvests every spare dollar into Evidence.com, AI features and enterprise expansion, so US dividend withholding and Form 67 are irrelevant.
• India tax: hold more than 24 months and pay 12.5% LTCG (no indexation); sell sooner and pay your slab rate. This is Section 112, not the friendlier 112A.
• The trap most miss: directly-held AXON is a US-situs asset — above $60,000, your estate faces up to 40% US estate tax, with no India-US treaty relief. At a share price in the hundreds, that ceiling is closer than it looks.
• If your thesis is "US tech," QQQ already holds AXON; defence and aerospace ETFs (XAR, ITA) have only limited exposure because Axon screens as software, not pure defence.

Quick facts

Can an Indian resident buy it?	Yes — fully legal under the LRS
Ticker / exchange	AXON / Nasdaq
How	India-facing platform (Vested, INDmoney) or global broker (IBKR, Rovia)
Minimum	A fraction of one share (fractional lets you invest an exact rupee amount)
Dividend	None — AXON has never paid one and reinvests cash into growth
India tax on gains	12.5% LTCG after 24 months; else your slab (Section 112)
Estate-tax risk	US-situs above $60k means up to 40%, no treaty relief
Annual compliance	Schedule FA disclosure, every year you hold

How to buy it — 3 steps

1. Open an account and finish KYC. Pick an India-facing platform (Vested, INDmoney) for a simple India-funded experience, or a global broker (Interactive Brokers, Rovia) for wider access. File your W-8BEN during onboarding — still good practice even with no current dividend, because it covers any future distribution. New to this? Start with how to invest in US stocks from India.
2. Fund it via the LRS. Remit from your Indian bank under the LRS (cap: $250,000 per financial year). 20% TCS applies above ten lakh rupees in a year — a creditable prepayment, not a cost. See LRS explained and the LRS and TCS calculator.
3. Place the order. AXON trades in the high hundreds of dollars per share, so one whole share is a meaningful rupee outlay — most Indian investors will buy a fractional rupee amount and accumulate over time.

The tax that actually matters

Axon pays no dividend, so the 25% US withholding and annual Form 67 dance — a recurring headache with Microsoft or Apple — does not apply. Your entire tax exposure is on capital gains when you sell, under Section 112 (foreign shares don't get the friendlier 112A treatment):

Holding period	Treatment	Rate
24 months or less	Short-term	Your slab rate (up to roughly 30% plus surcharge)
More than 24 months	Long-term	12.5%, no indexation

Worked example. Buy 3 shares at $560 when USD/INR is 86 → cost 1,44,480 rupees. Sell 28 months later at $680 when USD/INR is 88 → proceeds 1,79,520 rupees. Taxable gain 35,040 rupees; LTCG at 12.5% = 4,380 rupees. The high per-share price means even a 3-share position chews through 1.4 lakh rupees of LRS allowance up front — and the gain is computed in rupees, so a weaker rupee at sale amplifies your reported gain. Model your own with the US capital-gains calculator; full rules in how US stocks are taxed in India. For Form 67 context (relevant if you also hold dividend-paying US names), see dividend withholding and Form 67.

The $60,000 estate-tax trap

Directly-held AXON is a US-situs asset. If the holder dies with more than $60,000 of US-situs assets, the estate faces US estate tax up to 40% — and the India-US treaty does not cover estate tax, so there's no credit or relief. At AXON's high share price, even around 90 shares crosses the threshold, so the fix (holding through pooled or fund structures rather than direct shares) has to be a deliberate choice made before the position gets large. Full detail: the $60,000 estate-tax trap.

Buy the stock, or get Axon through an ETF?

If you want…	Best route
A concentrated bet on the hardware-plus-SaaS flywheel	AXON directly
"US tech with public-safety tailwinds" exposure	QQQ — AXON is a Nasdaq-100 constituent
Defence and aerospace exposure with some AXON	XAR or ITA — note AXON is classified more as software than defence, so weights are limited
The least single-stock risk	A broad ETF

Axon is a Nasdaq-100 member and sits inside QQQ at a smaller weight than the megacaps. Defence ETFs like XAR and ITA include AXON only lightly because it screens as application software, not a pure defence prime. None of these routes give the concentrated exposure direct ownership does — but they avoid single-name execution risk and offer cleaner estate-tax treatment. Compare in direct stocks vs US ETFs and best US ETFs for Indian investors; the broader case is in US ETFs for Indians.

The business in one screen

What it is: Axon sells hardware that lands the customer — Tasers, body-worn cameras, in-car video, drones — and converts that install base into recurring software revenue via Evidence.com (cloud digital-evidence management), real-time operations, AI auto-redaction, and a draft-report writer. ARR is growing more than 30% YoY, net retention is well over 100%, and TAM expansion into enterprise (retail loss-prevention, healthcare) and federal/military procurement widens the runway beyond US state and local police.

Bull case	Bear case
Hardware-plus-SaaS flywheel — sticky once a department is installed	ASR (annual subscription per officer) saturation in US police market
Evidence.com is the near-monopoly cloud for US law enforcement	Premium valuation on most EV/sales and EV/EBITDA metrics
AI features (draft-report, auto-redaction) raise switching costs	Regulatory and political risk in police-tech procurement cycles
Enterprise (retail, healthcare) and federal/military TAM expansion	International expansion still early outside the US
Drone optionality via the Skydio partnership	Motorola Solutions competing in adjacent radios and evidence niches

Exact valuation is in the live widget above — a quiet compounder with a powerful flywheel, priced at a premium that reflects retention and structural opportunity.

Our take

Verdict: BUY — Axon is a quiet compounder with a powerful flywheel, a clean tax profile (no dividend), and structural tailwinds in public safety and beyond.

• Hardware lands, software locks in. Tasers and body-cams are the wedge; once Evidence.com and the draft-report writer are embedded in a department's workflow, switching costs are punishing. ARR above 30% and net retention over 100% are the visible output.
• TAM expansion is real. State and local police were the beachhead; federal and military contracts, retail loss-prevention and healthcare now add incremental dollars on top of a growing core. The Skydio drone partnership is free optionality.
• Unusually clean tax profile. No dividend means no 25% US withholding, no annual Form 67, no double-tax friction — just a pure Section 112 capital-gains decision when you sell. Fits as a high-conviction satellite for an Indian investor without recurring tax admin.

Compliance note. Vested.blog is not a SEBI-registered Research Analyst. The above is an editorial opinion for educational illustration only — not investment advice and not a regulated stock recommendation. Vested.blog is published by Rovia; the publisher and its affiliates may hold positions in stocks discussed. Make your own decisions or consult a SEBI-registered advisor.

Risks to size for

• Valuation premium: AXON trades expensive on most EV/sales and EV/EBITDA screens. Growth and retention justify a premium, but they leave little margin for an execution slip or soft renewal cycle.
• Procurement and political risk: police-tech budgets can swing on local politics, federal funding cycles, and news incidents. A single name is far more exposed than an index.
• Currency: your return is in USD but you spend rupees — see the rupee-dollar effect.

Two things people forget

• Schedule FA: disclose AXON in Schedule FA of your ITR every year you hold it — even if bought and sold within the year, even at a loss. Non-disclosure carries Black Money Act penalties. Because AXON pays no dividend, you skip Form 67 — but Schedule FA is non-negotiable. Use the Schedule FA helper.
• Position size: a single mid-cap, however well-moated, is not an index. Size AXON as a satellite, not a substitute for a broad ETF — and remember the high per-share price means a few-share position can crowd out diversification fast.

Bottom line

Buying AXON from India is easy and legal. What needs thought isn't the buying — it's that AXON is a Section-112 capital-gains play (12.5% after 24 months), a US-situs asset with a $60k estate-tax trap that arrives fast at a high share price, and a single mid-cap that needs disciplined position sizing. The upside versus dividend-paying megacaps: no recurring 25% withholding and no Form 67 work. If your real thesis is "US tech with public-safety tailwinds," QQQ gives partial exposure. For accounts and options, start at the US investing hub.

---

This article is general information, not personalised investment, tax, or legal advice. Rules, rates, and thresholds described here are as of 2026 and can change; verify the current position and consult a qualified advisor before acting.